SS&C Technologies R&D increased by 2.2% to $134.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.3%, from $129.10M to $134.60M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 5.2% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $100.80M | $97.70M | $108.50M | $105.80M | $118.40M | $107.60M | $115.50M | $118.20M | $119.60M | $117.70M | $118.30M | $120.90M | $128.70M | $131.30M | $136.80M | $129.10M | $128.10M | $118.60M | $131.70M | $134.60M |
| QoQ Change | — | -3.1% | +11.1% | -2.5% | +11.9% | -9.1% | +7.3% | +2.3% | +1.2% | -1.6% | +0.5% | +2.2% | +6.5% | +2.0% | +4.2% | -5.6% | -0.8% | -7.4% | +11.0% | +2.2% |
| YoY Change | — | — | — | — | +17.5% | +10.1% | +6.5% | +11.7% | +1.0% | +9.4% | +2.4% | +2.3% | +7.6% | +11.6% | +15.6% | +6.8% | -0.5% | -9.7% | -3.7% | +4.3% |